Tradestie Institutional Equity Comparison Engine

BCAX vs EIKN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BCAX Overall Edge

BCAX Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bicara Therapeutics Inc. Common Stock (BCAX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EIKN at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against EIKN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BCAX N/M vs EIKN N/M Fwd P/E
Growth & Margin Winner BCAX
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner BCAX
1Y -32.8% vs -64.6% ยท 52W Pos 7% vs 2%
Options & Structure Winner BCAX
BREAKDOWN (23rd %ile IV) vs UNCLASSIFIED (N/A IV)
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.58
-4.39% 1D
Market Cap $671.2M
1M Return -42.91%
1Y Return -32.82%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
EIKN US Equity
EIKN
Institutional Equity
$5.31
-11.2% 1D
Market Cap N/A
1M Return -28.44%
1Y Return -64.6%
Forward P/E N/M
Unified AI Score
43.2 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BCAX -32.82% EIKN -64.6% Spread: +28.04 pp (BCAX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BCAX TTM Op. Margin: 0.0% EIKN TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs EIKN. Trailing 12-month operating profitability (BCAX 0.0% vs EIKN N/A) and valuation multiples (BCAX N/M vs EIKN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BCAX (7) vs EIKN (1)
Institutional Metric BCAX EIKN Criterion Row Winner
Market Capitalization Scale $671.2M N/A Larger Scale BCAX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth BCAX
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin BCAX
Net Profit Margin Profitability 0.0% N/A Higher Margin BCAX
Return on Equity (ROE) Capital Efficiency -54.2% N/A Higher ROE BCAX
52-Week Range Position Momentum 7% ($8โ€“$31) 2% ($5โ€“$17) Stronger Trend BCAX
Beta / 30D Volatility Risk Regime 1.41ฮฒ ยท 184% Vol 2.03ฮฒ ยท 131% Vol Lower Realized Risk EIKN
Unified Institutional Score Composite Signal 52.1 / 100 (HOLD) 43.2 / 100 (HOLD) Higher Composite BCAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BCAX vs EIKN Buy Guide
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EIKN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EIKN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BCAX nor EIKN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.